The Authors Reply:  by Nessim, Sharon J. et al.
early as in 1989, by Coronel et al.3 This effect was also
demonstrated again by our group in 2004 in patients on
peritoneal dialysis (PD) with an angiotensin receptor blocker
(irbesartan); besides the decrease of peritoneal protein leakage
and proteinuria, irbesartan was also shown to induce changes
in other peritoneal membrane functions.4 Both studies are
mentioned by Kolesnyk et al.5 in their recent review as the
ﬁrst studies in PD patients with this approach.
Studies with ACEIs, angiotensin receptor blockers, or other
substances that can modify peritoneal transport and maybe
improve technique survival still are needed, but we wish to
point out our modest contribution.
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The Authors Reply: We thank Dr Coronel for his
comments.1 Indeed, over two decades ago, Coronel et al.2
examined the effects of blockade of the renin–angiotensin–
aldosterone system (RAAS) on peritoneal membrane function.
Although the two studies mentioned were both small with
a short exposure time to RAAS blocking agents,2,3 they were
the earliest studies to report the effect of blocking the RAAS
on peritoneal membrane function in peritoneal dialysis
patients, setting the stage for the subsequent, larger-scale
observational studies by Kolesnyk et al.4,5 Unfortunately, we
were limited in the number of references for this mini-review,
and did not have the opportunity to discuss these smaller
early studies.
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The missing ‘interstitial vasculitis’
To the Editor: In a recent review on acute interstitial
nephritis (AIN),1 the authors state that AIN may be
associated with systemic disorders such as sarcoidosis,
Sjogren, or systemic lupus erythematosus, but they did not
mention the ‘interstitial vasculitis’, that is, AIN as the only
expression of renal vasculitis.
However, the occurrence of an involvement conﬁned to
the capillaries of renal tubular and interstitial structures in
the setting of systemic vasculitides has been clearly stated in
previous papers published by the European Vasculitis Study
group2 and others.3
Although interstitial vasculitis associated with glomerular
vasculitis is a common observation, interstitial vasculitis as
the only expression of renal involvement in systemic
vasculitides is a rare entity reported in 1% of cases. Pathogenic
mechanisms are presumed to be the same as described in
systemic vasculitis, eventually leading to the destruction of
the capillary walls of peritubular and interstitial capillaries
due to the consequences of inﬂammatory reaction from the
inﬁltrated cells.
However, the most intriguing point is the unknown
reasons for which the occurrence of this kind of vasculitis
only conﬁned to the tubular and interstitial capillary walls is
so rare an event. Some reports of the literature3,4 and our
personal experience in one case might suggest the existence
of a speciﬁc nosographic entity characterized by the co-
existence of giant cell (temporal) arteritis, polymyalgia
rheumatica, and renal interstitial vasculitis. Therefore, we
Table 1 | Etiology of biopsy-proven acute interstitial nephritis
(modified from Praga and Gonza´lez1)
Drugs Antibiotics, NSAIDs, acyclovir, allopurinol,
furosemide, omeprazole, etc.
Infections Bacteria, viruses, others
Associated with
systemic diseases
Sarcoidosis, Sjogren, systemic lupus
erythematosus, vasculitis
Idiopathic Anti-TBM, etc.
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